Taking Digital Health from 0-to-n

Taking Digital Health from 0-to-n

Innovation is a fascinating topic. Every once and a while, the world witnesses something extraordinary like discovery of amino acids determining a protein’s 3 dimensional shape by Christian Anfinsen or development of an AI system that predicts 3D protein structures by AlphaFold -an offspring of Google Deepmind.

These are innovations that Peter Thiel, the co-founder of PayPal, Palantir Technologies and successful other innovative businesses, refers to as 0-to-1. It’s exhilarating; it provides the opportunity to see things no one has ever seen before, like landing on the moon. It is literally out of this world. But the ultimate value comes from those who can take the exhilarating – the unprecedented – and make it simple and accessible—providing space travel not only to a handful but to all people who dare to dream big. This is 1-to-n. This is what disrupting innovation is about – scaling the unscalable, making the disruption the norm.

Digital health is no exception. Pharma industry and companies have seen the value of many 0-to-1 opportunities and are in the midst of realizing the ultimate value by bringing them 1-to-n. Amongst many others, here are a few of the examples I am the most fascinated with:

Throughout drug discovery, companies harness machine learning to make better decisions sooner, for instance, to analyze years of results and predict which compounds could be active against specific biological mechanisms. During drug development, novel study endpoints or integrating digital endpoints help better understand every aspect of the patient experience. Another example is connected health, such as apps that connect to your blood glucose meter and calculate your insulin dose. At this stage, in almost all therapies, companies from startup to large pharma, consider it a competitive necessity.

Digital therapeutics (DTx) are also exiting their phase of 0-to-1’ization. DTx delivers therapeutic interventions directly to patients using evidence-based, clinically evaluated software to manage and prevent a broad spectrum of diseases.

The last example is data and analytics ecosystems that leverage the millions of patient years of data to expand existing therapeutics into either new indications or patient populations while allowing to learn more about the underlying biology.

The 0-to-1’s are often the ones everyone hear most about. However, I am convinced that in order to be able to reimagine medicine with data and digital to improve and extend people’s lives, the 1-to-n’s should materialize. Understanding that it’s no longer about driving a digital transformation but industrializing transformation in a digital world, I am committed to continue industrializing the ability of driving innovation from 0-to-n and fully integrate data science and digital technology in our business models, in other words, bringing them from 0-to-n

The video: From 0-to-n

To learn more about the technology industry and its focus on diversity and inclusion, visit Bruno Villetelle’s monthly blog at BrunoVilletelle.com.

The Power of Diversity and Inclusion –  Gender Impact of Women

The Power of Diversity and Inclusion – Gender Impact of Women

In recent years, the focus on promoting diversity and inclusion has become a greater focus in the job force, particularly when it comes to the benefits of having women within the workplace. The growth of women in the workplace has helped lead to a transformation of how the workforce functions as a whole. This has become especially apparent for the impact of women within the technology sector. Digital health and technology expert Bruno Villetelle had the opportunity to speak with two prominent women within technology, named Elizabeth (Liz) Theophille, and Adama Ibrahim.

Technology expert Liz Theophille had the opportunity to speak on her experience as a woman working with the technology sector and what advantages she believes that women can bring to the workplace. In addition to helping to transform the workplace, she has seen that women tend to be very intuitive and understand how to employ strategic thinking and problem-solving skills when faced with difficult situations. 

Additionally, while there has been significant progress for women in recent years, she believes that there is still a lot of work to be done to achieve true diversity and inclusion. Given that Liz was only one of two females to complete her college program, the need for greater diversity and inclusion in the workplace remains high. 

For Adama Ibrahim, her experiences have been positive since beginning her career within technology, specifically because of the opportunity to work with other up-and-coming female professionals. Having the chance to work with other successful females in technology has allowed her to thrive in her own professional role. Not only has work with other females been beneficial in developing her own skills, but it encourages her to put her best foot forward each day. 

The attention to detail, strategy-building capabilities, and overall trusting approach that women take can help improve the way that countless industries function. This is especially true within the technology industry and will only continue to shift how the workplace functions in the coming years. 

To learn more about the technology industry and its focus on diversity and inclusion, visit Bruno Villetelle’s monthly blog at BrunoVilletelle.com.

To All Innovators: Diversity Wins!

To All Innovators: Diversity Wins!

This article was originally published on Bruno’s LinkedIn

It is widely believed that diversity is essential to innovation, and for good reason. Studies have found that companies with diverse leadership teams are 36% more likely to be profitable and generate 19% higher innovation revenue. Diversity is generally defined as the condition of having or being composed of differing elements or qualities. This being the definition, we are all diverse, so ensuring integrity and equity is of utmost importance considering that people can only be their best if they are able to express themselves freely without any concerns about their race, culture, gender identity, or sexual orientation. Ensuring integrity and equity is a fundamental part of being a leader.

Further developing my ability to be an inclusive leader has been full of self-growth and learning. I developed three strong beliefs on why diversity, inclusion, and equity are not only a human right responsibility, they are also critical to being a successful leader, and in business. Lessons of three decades driving innovation as an aspiring inclusive leader:

Integrate Diverse Perspectives

It sounds obvious but it starts with considering diverse point of views and needs of others, and learning how to tactfully navigate conflict situations. Composing diverse teams is critical to achieve collective success across differences yet it is just a starting point. Offering a diverse team an equitable and safe environment to express themselves freely is essential. The lines between private and work life are blurred, now more than ever, and we should expect people to bring their true self to the team. When we can share who we are, in the spirit of inclusivity and understand, empathize, and learn from one another, then we can generate new ideas, truly collaborate, drive innovation, better understand our stakeholders and better serve patients. Diversity and inclusion have been the topic across the globe for years now. Yet, the sad reality is those from underrepresented groups are still not treated equitably and often feel they do not have a voice. I am committed to be the epitome and voice of genuine leadership and engagement, which has led me to become one of Novartis’ diversity champions.

Build Interpersonal Trust

Another critical element to ensuring diversity and inclusion is the ability to establish rapport by finding common ground while simultaneously valuing perspectives that differ from my own. We can expect people to fully focus on and provide maximum contribution only if they do not spend their time and energy to censor themselves at work. The effort required to keep their true selves hidden can lead to isolation and feeling isolated at work has negative effects on both the lonely individual and the wider organization. When each of us can bring our authentic selves to work, we are more productive, engaged and happy. Novartis recently organized a Global Pride Webcast and we had the opportunity to hear from Gareth Thomas, international rugby legend to talk about his coming out publicly while still playing. He was then asked, if this would compromise his performance in the athletic field. Gareth responded, “My performance can only get better. I can run faster, jump higher as I do not have to carry that heavy load on my shoulders anymore”. His words resonated deeply.

Have an impact

In the end, embracing diversity is about turning good intentions into concrete results. It calls for the willingness to confront difficult topics and invest in bringing people of all backgrounds along to achieve meaningful results. In the innovative medicines space, we can best serve society and reimagine medicine for our global patient population only if we build a workplace that represents our global patient population. A ProPublica analysis reported that “black people and Native Americans are under-represented in clinical trials of new drugs, even when the treatment is aimed at a type of cancer that disproportionately affects them.” It is critical that innovative therapies include an understanding of impact across a diversity of patient populations, including under-served communities who could greatly benefit from these treatments. Novartis is committed to increase patient diversity in drug development; the most meaningful impact can be done by diverse people for diverse people.

I am proud to be working at the first global pharmaceutical company to uphold the United Nations Standards of Conduct for Business, tackling discrimination against Lesbian, Gay, Bisexual, Trans and Intersex (LGBTI) people. A company that appreciates the diversity not only to meet human rights responsibilities, yet as an active agent of change. When we allow for the pooling of unique cultural and experiential backgrounds, people find themselves in the best environment to thrive in, and unique and winning strategies are sure to follow. It is my belief and personal commitment. What’s yours?

Artificial Intelligence in Life Science — Demystifying the Buzz

Artificial Intelligence in Life Science — Demystifying the Buzz

This article was originally published to Bruno’s LinkedIn.

The Biotechnology Innovation Organization held its annual convention digitally this year, as part of which I had the opportunity to join the panel, “Demystifying Buzzwords – How Artificial Intelligence and Machine Learning are being used Now in the Life Sciences” with esteemed professionals [1] from all corners of the biotechnology industry.

The discussion is well-timed. Over the past decade we have seen the convergence of massive data sets, near-unlimited computing power, and advanced data science. The most pioneering biotechnology companies have moved beyond the hype. They now use AI and ML to turbo-charge efficiencypower up knowledge, and cut time from data to evidence.

Turbo-Charge Efficiency

AI does more than making a biotechnician’s job easier. The ability to analyze a torrent of data and relate it to tricky questions and challenges allows us to reach new depths and heights. AI and ML broaden our horizons as well. We might all need to become data scientists at some point to leverage the wealth of opportunities.

AI and ML serves as a “force multiplier” as Krishnan Nandabalan described it. After hitting a bottleneck back in 2015, InveniAI started using AI and ML to automate steps which led them to improved efficiency and enhanced analytical capabilities. Similarly, at Centrexion, AI and ML helped Kerrie Brady and the team to “bite big and chew hard” so even as a team of 6, they were able to manage five development projects.

When AI and ML apply to every part of the value chain, these technologies can promote efficiency, effectiveness, and increase probability of success. At Novartis, we are embedding AI and ML across the drug development value chain. We have many initiatives to maximize the value of these technologies to make sure they are not just widespread but also have depth.

Power Up Knowledge

Some professionals think that AI doesn’t just stand for Artificial Intelligence — it is an Accelerator of Innovation. In describing this technology, Moira Gunn said, “There’s no doubt about it; once you’re able to grasp it and put it to work, it accelerates innovation as we know it. That’s brand new, and that’s one of the reasons that our whole industry could change. Not from a test tube, but from data and from information.”

Some also define AI as Augmented Intelligence. AI doesn’t exist and operate in a vacuum; humans are critical to assess the reliability of the input and output, and synthesize collected data further. Aashish Kachru addressed this symbiotic relationship and advised us to “Embrace the job displacement that’s going to come as a result of AI, and move yourself towards higher skill values where you’ll be needed.”

The current global pandemic creates one such circumstance in which higher skill values are necessary. COVID-19 has led to a great deal of renewed connectivity and openness across the pharma industry. Technology such as Natural Language Processing has enabled this effort, scanning millions of publications and tapping into global knowledge to answer an individual team’s questions. An individualistic line of thinking is far too narrow when it comes to AI and ML. The panel highlighted the opportunity to refine the life sciences ecosystem, allowing companies to leverage their strengths and pool decentralized knowledge, as it can help individuals and healthcare professionals make the best informed decisions.

Cut Time from Data to Evidence

Novartis’ data42 program applies advanced analytics to derive medical insights from 2 million patient-years of data. We have primarily focused on bringing that data together and making it AI and ML-ready. These insights contribute to our increasing understanding of diseases and medicine, thereby enhancing R&D decision-making and ultimately #reimagining drug discovery and development by cutting the time from data to evidence.

But it all started with data. This is the condition for knowledge-workers really to be knowledge-workers, as opposed to data janitors and information engineers, creating room for operational, analytical, and experiential value growth, thereby expanding our capabilities.

According to multiple analyses, it can take over a decade to bring a new drug to patients, and only one out of ten drugs is successful. Early AI and ML opportunities have shown the potential to cut years off this timeline and maximize the probability of success. For which, as several panelists pointed out, making AI and ML part of the value chain end-to-end is the key.


The hype that AI and ML are disrupting the way we work is true, to an extent. AI and ML lead to reduced company costs and improved customer experiences, while Price Waterhouse Coopers reports that AI alone is expected to have a $15.7 trillion economic impact by 2030.

Completely in line with Brian Martin stating that “we have moved from myth to value”. As he elaborated, AI and ML “deliver the momentum to change”. The life sciences has become a digital industry powered by AI and ML. For us at Novartis, it is not “if” or “when” AI and ML will help us in our commitment to reimagining medicine. Now, the focus is on scaling it across the entire organization to fuel our unbossed, inspired and curious culture.

I’d like to extend a word of thanks to my esteemed co-panelists, all of whom shared great insights that did wonders to demystify AI an ML and I look forward to continuing and broadening these conversations.

[1] NPR’s Tech Nation host Moira Gunn moderated the panel, which included Altruista Health CEO Aashish Kachru InveniAI LLC President and CEO Krishnan Nandabalan, GSK Consumer Healthcare Director of Search and Evaluation Michael Keane, AbbVie Head of AI in R&D Information Research and Senior Principal Data Scientist Brian Martin, Centrexion Cofounder and former CBO Kerrie Brady, and myself.


Connectivity and Openness in the COVID-19 Era

Connectivity and Openness in the COVID-19 Era

This article was originally published on Bruno’s LinkedIn

Many journalists and bloggers use “unprecedented” to describe our current situation. No word is more appropriate. Communities around the world are engaging in an epic struggle to mitigate the spread and impacts of COVID-19. We are indebted beyond reconciliation to healthcare professionals and caregivers working on the front-lines of the pandemic. There is much to learn from the COVID-19 outbreak. In particular, two lessons cannot escape attention: 1) Embracing data science and digital technology is no longer optional for our healthcare systems, and 2) Open collaboration and innovation are essential to #reimaginingmedicine.

Collaboration Between Life Science Companies

It is clear that COVID-19 is not a sequestered issue—it is a global pandemic that has traveled far and wide to impact some of our world’s most vulnerable populations. For this reason, the collaborative efforts of life science companies as they work to minimize and mitigate the overall impact of the novel coronavirus was much needed and unheard-of. The Bill and Melinda Gates Foundation’s efforts to pool resources across 15 life science companies is especially notable. This group will share their libraries of resources, which include unique molecular compounds that could potentially turn the tides in the public health sector’s favor. Those molecular libraries have found a home in the COVID-19 Therapeutics Accelerator, a platform developed by the Gates Foundation. Researchers use this tech to quickly identify which compounds and options are most likely to make a positive impact. Combined with accelerated vaccine and therapeutic trials and the combination of data from a multitude of countries and sources, the initiative has the potential to create a step-change on both national and international levels.

Collaboration Between Healthcare Providers and Tech Companies

Stay-at-home and quarantine orders are limiting people’s access to healthcare around the world. For some people,healthcare providers are able to visit them at their home, but this is not an option for most. Where home delivery is not possible, even access to medication is disrupted. Technologies such as home assistants and telemedicine are enabling healthcare providers to reach their most vulnerable patients without making direct, person-to-person contact. Hospitals are using AI combined with sensors for a variety of tasks, from tracking patient temperatures to detecting acute respiratory conditions. These technologies allow patient monitoring without putting healthcare providers at more risk for infection. Providers have utilized drones to reach those who cannot leave their homes whether due to compromised immune systems or mild symptoms and to drop off medical supplies from rural locales in Ghana to cities across the United States. Their service include prescription drugs, medical implements such as swabs and masks, and even COVID-19 testing kits. Organizations, including the World Health Organization, IBM, Oracle, Microsoft, and other tech companies, government agencies, and international health organizations are partnering in building the blockchain-based open data hub called MiPasa. It is poised to enable rapid and precise detection of COVID-19 carriers and infection hotspots around the world.

Health Authorities’ Overall Collaborative Position

As the crisis has played out, health authorities have seen the fruit of their digitalization efforts and are doubling down on these technologies – publishing and advocating positions that favor even further acceleration. The CDC, FDA and WHO, have recognized that digital health technologies can provide powerful tools for public health officials and the public in the management of the COVID-19 response. GermanySwitzerland and many more countries launched a dedicated hackathon in response to COVID-19. The Health Innovation Hub, established by Germany’s Ministry of Health, published a list of trusted telemedicine services. The Mayo Clinic and the Minnesota state health department developed an artificial intelligence-powered tool to determine which areas of the state were most at risk for spreading and contracting COVID-19. The National Institutes of Health’s Accelerating COVID-19 Therapeutic Interventions and Vaccines initiative launched in an unprecedented effort to bring together health agencies and members of the pharmaceutical industry in response to the current and future pandemics.

Connectivity and Openness, the “New Normal”?

As we begin to re-open businesses and schools, we should remember the value of collaboration within the healthcare ecosystem. Resource pooling, information accessibility, and new technologies played an important role in combating COVID-19. As usual, hindsight is “20/20” – it is hard to fathom what prevented us from unleashing this level of collaboration earlier. When we needed to stay physically apart, we saw the urgency to come together to combine our knowledge, skillsets and experience as illustrated above, but also in so many other examples.

These unprecedented times unearthed the need to move beyond the usual calls for open innovation: a need for connectedness, maybe deriving from Joy’s law, “no matter who you are, most of the smartest people work for someone else”. The state of urgency side-showed the prime focus on internal excellence, intellectual property protection and competitive vying and brought together people in totally new ways. I can not help asking, “what if” this connected openness, this #unbossed can-do mindset, were to become the real “new normal”?